Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

When our bodies are invaded by a virus, our immune systems make particular proteins called antibodies to help fight off infection.

Scientists working to quell the COVID-19 pandemic think it will be possible to figure out which antibodies are most potent in quashing a coronavirus infection, and then make vast quantities of identical copies of these proteins synthetically.

In an unusual move, the Food and Drug Administration today announced that is making it easier for doctors to try an experimental treatment for COVID-19 patients that uses plasma from people who had the disease and recovered.

There is scant evidence it works in people infected with the coronavirus, but the approach has been tried for other illnesses.

The federal government is now adding supercomputers to its tool set in the hunt for ways to stop COVID-19.

While health officials in the United States wait to see just how bad a public health challenge COVID-19 will pose, they still have to deal with an all-too-familiar challenge: flu.

It's been a bad flu season. Not the worst ever, but bad.

"It started very early this year," says Emily Martin, associate professor of epidemiology at the University of Michigan School of Public Health. She works with the Centers for Disease Control and Prevention collecting statistics about flu.

Viral infections can be very hard to treat. Just ask anyone who has a bad case of the flu.

But that's not deterring research groups around the world from looking for an effective therapy against the new coronavirus, although they know it won't be easy.

Right now scientists are trying to accomplish something that was inconceivable a decade ago: create a vaccine against a previously unknown virus rapidly enough to help end an outbreak of that virus. In this case, they're trying to stop the spread of the new coronavirus that has already infected tens of thousands of people, mainly in China, and given rise to a respiratory condition now known as COVID-19.

There's a mole on Mars that's making NASA engineers tear their hair out.

No, they haven't discovered a small, insectivorous mammal on the red planet.

The mole vexing engineers at the Jet Propulsion Laboratory in Pasadena is a scientific instrument known as the Heat Flow and Physical Properties Package, or HP3 — or just "the mole" — carried on NASA's InSight probe that landed on Mars a year ago.

It's not easy to treat viral infections. Just ask anyone with a bad cold or a case of the flu.

But scientists in Massachusetts think they may have a new way to stop viruses from making people sick by using what amounts to a pair of molecular scissors, known as CRISPR.

It's a gene editing tool based on a molecule that occurs naturally in microorganisms.

Tiny satellites are taking on a big-time role in space exploration.

CubeSats are small, only about twice the size of a Rubik's Cube. As the name suggests, they're cube-shaped, 4 inches on each side, and weigh in at about 3 pounds. But with the miniaturization of electronics, it's become possible to pack a sophisticated mission into a tiny package.

Locusts are not just a biblical plague. They're swarming around the world. Still. Again.

According to the Food and Agriculture Organization of the United Nations, the desert locust situation is serious in Yemen and at the Indo-Pakistan border.

Pages